Oncology Clinical Pathways Spotlight
This week in health care trends, our spotlight on clinical pathways in oncology includes updates about the cost of inpatient versus outpatient cancer therapy, the state of oncology private practices, and an ASCO statement on Medicaid reform.
The three articles below are from our dedicated Clinical Pathways e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check our e-magazine frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
In the last few decades, many cancer therapies have shifted from inpatient to outpatient administration. Along with this shift has come a shift in the way these therapies are reimbursed and a corresponding effect on the cost of drugs: “A report by the IMS Institute for Healthcare Informatics published in May 2014 found that the cost of cancer drugs has doubled in the United States in the last 10 years as a result of the 340B Drug Pricing Program created in 1992, which requires that drug manufacturers provide outpatient drugs to certain covered entities at significantly decreased costs.”
In a recent New York Times article, several practicing oncologists weigh in about the “dying breed” of the private oncologist. Dr. Jeffery Ward shares about the changes in his private practice since they sold to a hospital. The biggest difference: noticeably higher costs for patients and insurers alike.
This comprehensive statement about Medicaid reform was released by ASCO earlier this month. In it, ASCO sets forth their guiding hopes for Medicaid reform, including access to quality care from a cancer specialist for all cancer patients, clinical trial access for Medicaid patients, and coverage for genetic testing.